Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome

Pediatric Research

Volumn 67, Issue 2, 2010, Pages 150-157

  Simpson, Catherine M ^a,c   Smolich, Joseph J ^a,c   Shekerdemian, Lara S ^a,b,c   Penny, Daniel J ^a,b,c  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PALOSURAN; RECEPTOR BLOCKING AGENT; UROTENSIN II; VASODILATOR AGENT; 1 (2 (4 BENZYL 4 HYDROXYPIPERIDIN 1 YL)ETHYL) 3 (2 METHYLQUINOLIN 4 YL)UREA; 1-(2-(4-BENZYL-4-HYDROXYPIPERIDIN-1-YL)ETHYL)-3-(2-METHYLQUINOLIN-4-YL)UREA; DRUG DERIVATIVE; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; OXYGEN; QUINOLINE DERIVATIVE; UREA; UROTENSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG INSTILLATION; FEMALE; HEMODYNAMICS; HUMAN; LAMB; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MECONIUM; MECONIUM ASPIRATION; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZATION; ANIMAL; BLOOD; BLOOD PRESSURE; DISEASE MODEL; DRUG ANTAGONISM; HEART OUTPUT; METABOLISM; PATHOPHYSIOLOGY; PULMONARY ARTERY; SHEEP; TIME; UPREGULATION; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANIMALS, NEWBORN; BLOOD PRESSURE; CARDIAC OUTPUT; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; MECONIUM ASPIRATION SYNDROME; OXYGEN; PULMONARY ARTERY; QUINOLINES; RECEPTORS, G-PROTEIN-COUPLED; SHEEP; TIME FACTORS; UP-REGULATION; UREA; UROTENSINS; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATION;

EID: 77449104771     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e3181c345ea     Document Type: Article

References (32)

1. Shekerdemian LS, Ravn HB, Penny DJ 2002 Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 165:1098-1102
2. Shekerdemian LS, Penny DJ, Ryhammer PK, Reader JA, Ravn HB 2004 Endothe-lin-A receptor blockade and inhaled nitric oxide in a porcine model of meconium aspiration syndrome. Pediatr Res 56:353-358
3. Shekerdemian LS, Ravn HB, Penny DJ 2004 Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 55:413-418
4. Davis PJ, Shekerdemian LS 2001 Meconium aspiration syndrome and extracorpo-real membrane oxygenation. Arch Dis Child Fetal Neonatal Ed 84:F1-F3
5. Steinhorn RH, Morin FC III, Fineman JR 1997 Models of persistent pulmonary hypertension of the newborn (PPHN) and the role of cyclic guanosine monophos-phate (GMP) in pulmonary vasorelaxation. Semin Perinatol 21:393-408
6. Haworth SG 2006 Pulmonary endothelium in the perinatal period. Pharmacol Rep 58:153-164
7. Kuo C, Chen J 1999 Effect of meconium aspiration on plasma endothelin-1 level and pulmonary hemodynamics in a piglet model. Biol Neonate 76:228-234
8. Kuo CY 2001 Endothelin-A receptor antagonist prevents neonatal pulmonary hypertension in meconium aspiration in piglets. J Formos Med Assoc 100:420-423
9. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA 1999 Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282-286
10. Sun DJ, Yang JP, Sun YH 2006 [The expression and significance of urotensin II, nitric oxide, and C-type natriuretic peptide in hypoxia-induced pulmonary hypertension in rats.] Zhonghua Jie He He Hu Xi Za Zhi 29:185-188
11. Maguire JJ, Davenport AP 2002 Is urotensin-II the new endothelin? Br J Pharmacol 137:579-588
12. Qi J, Du J, Tang X, Li J, Wei B, Tang C 2004 The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart Vessels 19:81-88
13. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Muller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P 2004 Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1- yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a patho-physiological role of the urotensin System. J Pharmacol Exp Ther 311:204-212
14. Shiao SY, Ou CN 2007 Validation of oxygen saturation monitoring in neonates. Am J Crit Care 16:168-178
15. Smolich JJ, Soust M, Berger PJ, Walker AM 1992 Indirect relation between rises in oxygen consumption and left ventricular output at birth in lambs. Circ Res 71:443-450
16. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG 2002 Plasma urotensin II in heart failure. Lancet 360:545-546
17. Kitamura K, Tanaka T, Kato J, Eto T, Tanaka K 1989 Regional distribution of immunoreactive endothelin in porcine tissue: abundance in inner medulla of kidney. Biochem Biophys Res Commun 161:348-352
18. Snedecor GW, Cochran WG 1980 Statistical Methods. The Iowa State University Press, Ames, Iowa, pp 350-352
19. Gibson A, Wallace P, Bern HA 1986 Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen Comp Endocrinol 64:435-439
20. Bottrill FE, Douglas SA, Hiley CR, White R 2000 Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130:1865-1870
21. Gray GA, Jones MR, Sharif I 2001 Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cycloox-ygenase inhibition. Life Sci 69:175-180
22. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Polland K 2000 Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130:201-204
23. Fox WW, Gewitz MH, Dinwiddie R, Drummond WH, Peckham GJ 1977 Pulmonary hypertension in the perinatal aspiration syndromes. Pediatrics 59:205-211
24. Cornish JD, Dreyer GL, Snyder GE, Kuehl TJ, Gerstmann DR, Null DM Jr, Coalson JJ, deLemos RA 1994 Failure of acute perinatal asphyxia or meconium aspiration to produce persistent pulmonary hypertension in a neonatal baboon model. Am J Obstet Gynecol 171:43-49
25. Wiswell TE, Gannon CM, Jacob J, Goldsmith L, Szyld E, Weiss K, Schutzman D, Cleary GM, Filipov P, Kurlat I, Caballero CL, Abassi S, Sprague D, Oltorf C, Padula M 2000 Delivery room management of the apparently vigorous meconium-stained neonate: results of the multicenter, international collaborative trial. Pediatrics 105:1-7
26. Durand M, Snyder JR, Gangitano E, Wu PY 1990 Oxygenation index in patients with meconium aspiration: conventional and extracorporeal membrane oxygenation therapy. Crit Care Med 18:373-377
27. Budhiraja R, Tuder RM, Hassoun PM 2004 Endothelial dysfunction in pulmonary hypertension. Circulation 109:159-165
28. Djordjevic T, Gorlach A 2007 Urotensin-II in the lung: a matter for vascular remodelling and pulmonary hypertension? Thromb Haemost 98:952-962
29. Gibson A 1987 Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol 91:205-212
30. Ivy DD, Lee DS, Rairigh RL, Parker TA, Abman SH 2004 Endothelin B receptor blockade attenuates pulmonary vasodilation in oxygen-ventilated fetal lambs. Biol Neonate 86:155-159
31. Levy M, Maurey C, Dinh-Xuan AT, Vouhe P, Israel-Biet D 2005 Developmental expression of vasoactive and growth factors in human lung. Role in pulmonary vascular resistance adaptation at birth. Pediatr Res 57:21R-25R
32. Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, Abman SH 1992 Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus. Am J Physiol 262:H1474-H1481